Skip to main content

Immuneering Corp

corporate_fare Company Profile

Immuneering Corp

IMRX·NASDAQ·Life Sciences·CIK 0001790340

We are a late-stage clinical oncology company focused on developing and commercializing a new category of anti-cancer medicines called Deep Cyclic Inhibitors. Deep Cyclic Inhibition® ("DCI") is a novel mechanism designed to deprive tumor cells of the sustained proliferative signaling needed for rapid growth, while sparing healthy cells by maintaining a cadenced, normalized level of signaling. Our Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the mitogen-activated protein kinase ("MAPK") pathway. This approach aims to improve durability and tolerability, differentiating it from chronically targeted precision therapies often limited by toxicity, resistance, or application to specific mutations. Our lead product candidate is atebimetinib (IMM-1-104), an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinase kinase ("MEK"). Atebimetinib is designed to improve durability and tolerability across various cancer indications, including MAPK pathway-driven tumors like pancreatic cancer. We are initiating a Phase 3 clinical trial for atebimetinib, named the MAPKeeper 301 trial. This trial will evaluate atebimetinib in combination with modified gemcitabine/nab-paclitaxel ("mGnP") in first-line pancreatic cancer patients. The MAPKeeper 301 is a global Phase 3 registrational trial comparing atebimetinib (320 mg QD) plus mGnP to standard of care gemcitabine/nab-paclitaxel ("GnP") alone in first-line metastatic pancreatic ductal adenocarcinoma ("PDAC"). The primary endpoint is overall survival, with secondary endpoints including progression-free survival, overall response rate, disease control rate, and quality of life measurements. We plan to enroll approximately 510 patients in MAPKeeper 301, divided equally across the two arms.

Immuneering Corp (NASDAQ:IMRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for IMRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for IMRX spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Pancreatic Trial Enrollment Runs Ahead of Schedule
  • Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Enrollment Runs Ahead of Schedule
  • Atebimetinib Data Show Weight Preservation Doubles Survival in Pancreatic Cancer
  • Immuneering Q2 2026: $182.7M Cash, Phase 3 Pancreatic Cancer Trial Underway, 17.3-Month Survival Data
  • Atebimetinib Preclinical Data Published in Cancer Research Shows Broad Activity and Favorable Tolerability

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$56.02M
Diluted EPS
-$1.27
Op. Cash Flow
-$45.34M
Free Cash Flow
-$45.49M
Operating Income
-$59.38M
Cash & Equivalents
$128.65M
Debt / Equity
0.00×
Shares Outstanding
44.01M sh
Source: 10-K · filed 2026-03-06 · accession 0001790340-26-000042

Short Interest & Short Volume

19.20 days to cover

FINRA reported short interest of 14,595,733 shares in IMRX as of the October 30, 2026 settlement, a 10.6% decrease from the prior period — about 19.2 days to cover at its recent average daily volume. On November 20, 2026, 32.6% of IMRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,595,733 shares as of October 30, 2026
Change vs prior period▼ 10.6%
Days to cover19.20 at avg daily volume of 760,062
Daily short volume (FINRA facilities)32.6% of 631,968 shares on November 20, 2026
5-day average short volume40.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$3.33 -1.48% today
52-week range · as of 2026-10-29 $3.33 – $8.48
Market cap
$218.9M
Volume
1.5M (1.8× avg)
3-mo avg 794.9K
Live data · 2026-11-22 05:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IMRX - Latest Insights

IMRX
Oct 29, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.33 info
Change: -$0.690 (-17%) info
Market Cap: $218.899M info
IMRX
Oct 29, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.33 info
Change: -$0.690 (-17%) info
Market Cap: $218.899M info
IMRX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.36
Real-time Price: $3.33 info
Change: -$1.03 (-24%) info
Market Cap: $218.899M info
IMRX
Aug 05, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.33 info
Change: -$0.900 (-21%) info
Market Cap: $218.899M info
IMRX
Jul 21, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.33 info
Change: -$1.18 (-26%) info
Market Cap: $218.899M info
IMRX
Jun 15, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.33 info
Change: -$0.860 (-21%) info
Market Cap: $218.899M info
IMRX
Jun 01, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $3.33 info
Change: -$1.17 (-26%) info
Market Cap: $218.899M info
IMRX
Jun 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.84
Real-time Price: $3.33 info
Change: -$2.51 (-43%) info
Market Cap: $218.899M info
IMRX
May 21, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.51
Real-time Price: $3.33 info
Change: -$2.18 (-40%) info
Market Cap: $218.899M info
IMRX
May 16, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $3.33 info
Change: -$1.79 (-35%) info
Market Cap: $218.899M info
IMRX
May 15, 2026, 7:52 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $3.33 info
Change: -$1.75 (-34%) info
Market Cap: $218.899M info
IMRX
May 15, 2026, 7:43 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.10
Real-time Price: $3.33 info
Change: -$1.77 (-35%) info
Market Cap: $218.899M info
IMRX
May 15, 2026, 7:35 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.10
Real-time Price: $3.33 info
Change: -$1.77 (-35%) info
Market Cap: $218.899M info
IMRX
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.66
Real-time Price: $3.33 info
Change: -$2.33 (-41%) info
Market Cap: $218.899M info
IMRX
Mar 06, 2026, 8:29 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $3.33 info
Change: -$1.56 (-32%) info
Market Cap: $218.899M info
IMRX
Mar 06, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.92
Real-time Price: $3.33 info
Change: -$1.59 (-32%) info
Market Cap: $218.899M info
IMRX
Mar 06, 2026, 7:56 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $4.98
Real-time Price: $3.33 info
Change: -$1.65 (-33%) info
Market Cap: $218.899M info
IMRX
Jan 07, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.62
Real-time Price: $3.33 info
Change: -$3.29 (-50%) info
Market Cap: $218.899M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets